BDBM282820 6-(4-(4-fluorophenyl)-1-(3- (hydroxymethyl)cyclobutyl)-1H-imidazol-5- yl)imidazo[1,2-b]pyridazine-3-carbonitrile::US10287295, Example 27'::US9884868, Example 27'

SMILES: OCC1CC(C1)n1cnc(c1-c1ccc2ncc(C#N)n2n1)-c1ccc(F)cc1

InChI Key: InChIKey=IWZYADDJULNIJB-UHFFFAOYSA-N

Data: 4 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 282820   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
TGF-beta receptor type-1 (Homo sapiens (Human))	BDBM282820 (6-(4-(4-fluorophenyl)-1-(3- (hydroxymethyl)cyclobu...) Show SMILES OCC1CC(C1)n1cnc(c1-c1ccc2ncc(C#N)n2n1)-c1ccc(F)cc1 |(-4.26,-4.53,;-2.93,-5.3,;-1.59,-4.53,;-1.19,-3.04,;.29,-3.44,;-.1,-4.93,;1.63,-2.67,;3.09,-3.14,;4,-1.9,;3.09,-.65,;1.63,-1.13,;.29,-.36,;.29,1.18,;-1.04,1.95,;-2.37,1.18,;-3.84,1.66,;-4.74,.41,;-3.84,-.83,;-4.31,-2.3,;-4.79,-3.76,;-2.37,-.36,;-1.04,-1.13,;3.49,.83,;4.98,1.23,;5.38,2.72,;4.29,3.81,;4.69,5.3,;2.8,3.41,;2.4,1.92,)| Show InChI InChI=1S/C21H17FN6O/c22-15-3-1-14(2-4-15)20-21(27(12-25-20)16-7-13(8-16)11-29)18-5-6-19-24-10-17(9-23)28(19)26-18/h1-6,10,12-13,16,29H,7-8,11H2	PDB MMDB UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.600	n/a	n/a	n/a	n/a	7.4	25
Rigel Pharmaceuticals, Inc.; Bristol-Myers Squibb Company US Patent					Assay Description Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...				US Patent US9884868 (2018) BindingDB Entry DOI: 10.7270/Q20P122M
					More data for this Ligand-Target Pair
TGF-beta receptor type II (Homo sapiens (Human))	BDBM282820 (6-(4-(4-fluorophenyl)-1-(3- (hydroxymethyl)cyclobu...) Show SMILES OCC1CC(C1)n1cnc(c1-c1ccc2ncc(C#N)n2n1)-c1ccc(F)cc1 |(-4.26,-4.53,;-2.93,-5.3,;-1.59,-4.53,;-1.19,-3.04,;.29,-3.44,;-.1,-4.93,;1.63,-2.67,;3.09,-3.14,;4,-1.9,;3.09,-.65,;1.63,-1.13,;.29,-.36,;.29,1.18,;-1.04,1.95,;-2.37,1.18,;-3.84,1.66,;-4.74,.41,;-3.84,-.83,;-4.31,-2.3,;-4.79,-3.76,;-2.37,-.36,;-1.04,-1.13,;3.49,.83,;4.98,1.23,;5.38,2.72,;4.29,3.81,;4.69,5.3,;2.8,3.41,;2.4,1.92,)| Show InChI InChI=1S/C21H17FN6O/c22-15-3-1-14(2-4-15)20-21(27(12-25-20)16-7-13(8-16)11-29)18-5-6-19-24-10-17(9-23)28(19)26-18/h1-6,10,12-13,16,29H,7-8,11H2	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.25E+3	n/a	n/a	n/a	n/a	n/a	n/a
University of Wisconsin at Madison					Assay Description Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...				J Med Chem 51: 7243-52 (2008) BindingDB Entry DOI: 10.7270/Q2B85BFB
					More data for this Ligand-Target Pair
TGF-betaR1 T204D (Homo sapiens (Human))	BDBM282820 (6-(4-(4-fluorophenyl)-1-(3- (hydroxymethyl)cyclobu...) Show SMILES OCC1CC(C1)n1cnc(c1-c1ccc2ncc(C#N)n2n1)-c1ccc(F)cc1 |(-4.26,-4.53,;-2.93,-5.3,;-1.59,-4.53,;-1.19,-3.04,;.29,-3.44,;-.1,-4.93,;1.63,-2.67,;3.09,-3.14,;4,-1.9,;3.09,-.65,;1.63,-1.13,;.29,-.36,;.29,1.18,;-1.04,1.95,;-2.37,1.18,;-3.84,1.66,;-4.74,.41,;-3.84,-.83,;-4.31,-2.3,;-4.79,-3.76,;-2.37,-.36,;-1.04,-1.13,;3.49,.83,;4.98,1.23,;5.38,2.72,;4.29,3.81,;4.69,5.3,;2.8,3.41,;2.4,1.92,)| Show InChI InChI=1S/C21H17FN6O/c22-15-3-1-14(2-4-15)20-21(27(12-25-20)16-7-13(8-16)11-29)18-5-6-19-24-10-17(9-23)28(19)26-18/h1-6,10,12-13,16,29H,7-8,11H2	PDB MMDB NCI pathway Reactome pathway KEGG B.MOAD DrugBank GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.600	n/a	n/a	n/a	n/a	n/a	n/a
University of Wisconsin at Madison					Assay Description Assays for the compounds reported below were conducted in 1536-well plates and 2 mL reactions are prepared from addition of HIS-TGF-βR1 T204D or...				J Med Chem 51: 7243-52 (2008) BindingDB Entry DOI: 10.7270/Q2B85BFB
					More data for this Ligand-Target Pair
TGF-beta receptor type II (Homo sapiens (Human))	BDBM282820 (6-(4-(4-fluorophenyl)-1-(3- (hydroxymethyl)cyclobu...) Show SMILES OCC1CC(C1)n1cnc(c1-c1ccc2ncc(C#N)n2n1)-c1ccc(F)cc1 |(-4.26,-4.53,;-2.93,-5.3,;-1.59,-4.53,;-1.19,-3.04,;.29,-3.44,;-.1,-4.93,;1.63,-2.67,;3.09,-3.14,;4,-1.9,;3.09,-.65,;1.63,-1.13,;.29,-.36,;.29,1.18,;-1.04,1.95,;-2.37,1.18,;-3.84,1.66,;-4.74,.41,;-3.84,-.83,;-4.31,-2.3,;-4.79,-3.76,;-2.37,-.36,;-1.04,-1.13,;3.49,.83,;4.98,1.23,;5.38,2.72,;4.29,3.81,;4.69,5.3,;2.8,3.41,;2.4,1.92,)| Show InChI InChI=1S/C21H17FN6O/c22-15-3-1-14(2-4-15)20-21(27(12-25-20)16-7-13(8-16)11-29)18-5-6-19-24-10-17(9-23)28(19)26-18/h1-6,10,12-13,16,29H,7-8,11H2	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.25E+3	n/a	n/a	n/a	n/a	n/a	n/a
Rigel Pharmaceuticals, Inc.; Bristol-Myers Squibb Company US Patent									US Patent US9884868 (2018) BindingDB Entry DOI: 10.7270/Q20P122M
					More data for this Ligand-Target Pair